• Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

    Source: Buzz FX / 18 Mar 2025 10:51:25   America/Chicago


    News
    Article
    Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.
    Penpulimab (formerly AK105), an anti–PD-1 monoclonal antibody, has received approval from the National
    Read more...
Share on,